Hakan Paydak is a Cardiology physician. OpenAlex indexes 158 publications with 2,261 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4301 W Markham St # 532
Little Rock, AR 722057199
Telephone
501-686-8000Registry record last updated 3 May 2010.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20255 payments
- Abbott LaboratoriesProgram year20253 payments
- Boston Scientific CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.6%Beta blocker19.4%Metoprolol Succinate38%Carvedilol26%Metoprolol Tartrate16%Sotalol16%Sotalol Af3%Propranolol Hcl Er2%Part D<11 patientsAntiarrhythmic14.1%Flecainide Acetate50%Amiodarone Hcl27%Propafenone Hcl11%Multaq9%Dofetilide3%Part D<11 patients+ 13 more classes in this area
Blood & clotting
13.5%Factor Xa inhibitor12.5%Eliquis82%Xarelto18%Part D≥72 patientsP2Y12 inhibitor0.5%Clopidogrel100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
5.7%Potassium supplement4.3%Potassium Chloride100%Part D≥28 patientsSGLT2 inhibitor0.8%Jardiance100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prior Statin vs In-Hospital Statin Usage in Severe COVID-19: Review and Meta-Analysis
Current Problems in Cardiology
2023 - Direct Oral Anticoagulants Versus Warfarin in Left Ventricular Thrombus
American Journal of Therapeutics
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”